Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-121,800
Closed -$8.41M 547
2024
Q4
$8.41M Buy
+121,800
New +$8.77M 0.22% 139
2024
Q3
Sell
-20,000
Closed -$1.34M 531
2024
Q2
$1.34M Sell
20,000
-81,000
-80% -$3.14M 0.04% 284
2024
Q1
$2.74M Buy
+101,000
New +$2.83M 0.09% 196
2020
Q4
Sell
-31,300
Closed -$1.01M 422
2020
Q3
$1.01M Buy
+31,300
New +$900K 0.07% 214
2018
Q3
Sell
-90,000
Closed -$2.13M 326
2018
Q2
$2.13M Buy
+90,000
New +$2.32M 0.11% 206
2018
Q1
Sell
-32,500
Closed -$1.01M 392
2017
Q4
$1.01M Buy
32,500
+6,500
+25% +$192K 0.05% 235
2017
Q3
$811K Buy
+26,000
New +$495K 0.04% 247
2014
Q3
Sell
-96,300
Closed -$1.92M 304
2014
Q2
$1.92M Buy
+96,300
New +$1.43M 0.14% 150
2014
Q1
Sell
-5,000
Closed -$85K 263
2013
Q4
$85K Buy
+5,000
New +$76.6K 0.01% 206

Other funds holding INSM

J. Goldman & Co's INSM Position: Q1 2026 in Review

J. Goldman & Co increased its Insmed (INSM) stake by 287% in Q1 2026, buying an estimated $632K and bringing the position to 5,545 shares worth $907K. The position accounts for 0.03% of the portfolio, ranked #436.

J. Goldman & Co first reported a position in INSM in Q4 2013 and has held it in 25 quarters since. The position peaked at $7.19M in Q4 2024. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • J. Goldman & Co held 5,545 shares of Insmed worth $907K as of Q1 2026.
  • J. Goldman & Co bought 4,114 Insmed shares in Q1 2026, an estimated $632K.
  • Insmed made up 0.03% of J. Goldman & Co's portfolio in Q1 2026, its #436 holding.
  • J. Goldman & Co first reported a position in Insmed in Q4 2013 and has held it in 25 quarters since.
  • J. Goldman & Co's Insmed position peaked at $7.19M in Q4 2024.
  • 669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.